Searchable abstracts of presentations at key conferences in endocrinology

ea0068p30 | Abstracts | UKINETS2019

Nutrition in patients with gastro-entero-pancreatic (GEP) neuroendocrine tumours (NETs) and NETs of unknown primary

Batchelor Emily , Gibson Katie , Wall Lucy

Background: Patients with low grade GI tract (GEP) neuroendocrine tumours and low grade neuroendocrine tumours of unknown primary (LG NETs) often live for many years even in the context of advanced disease. Their nutritional status is important to maintain wellbeing. Both the tumour and its treatment can potentially affect nutritional status.Method: Patients attending routine follow up appointments with the NET team in Edinburgh were invited to participa...

ea0052p40 | (1) | UKINETS2017

Pancreatic VIPoma – a diagnostic and symptom control challenge

Jack Ross , Fineron Paul , Patel Dilip , Ritchie Stuart , Subedi Deepak , Wall Lucy

A case is reported of a man with stage IV grade 2 pancreatic VIPoma. At diagnosis he had several features which may have expedited the diagnosis including refractory diarrhoea containing undigested foodstuffs, alcohol-related flushing, electrolyte abnormalities and intestinal oedema on imaging. Symptom control was challenging. There was no benefit from creon, loperamide or codeine and escalation to both short and long acting somatostatin analogues was futile. Consistent with a...

ea0087p12 | Poster Presentations | UKINETS2022

SIRT: adrenocortical carcinoma and liver metastases

Baxendale-Smith Leo , El-Shakankery Karim , Wall Lucy , Gordon-Smith James

Introduction: Selective internal radiation therapy (SIRT) is a novel intervention used to treat both primary and metastatic malignant liver lesions. Adrenocortical carcinoma (ACC) is a rare cancer with limited treatment options; evidence for SIRT use in ACC liver metastases is limited to case reports only. In this case we report prolonged and successful disease control using recurrent SIRT in a gentleman with liver-limited ACC.Case study: A 49-year-old g...

ea0046p17 | (1) | UKINETS2016

UK Phase IV, Observational study to assess Quality of Life in patients (pts) with pancreatic neuroendocrine tumours (pNETs) receiving treatment with Everolimus: The “Real-World” OBLIQUE Study

Ramage John , Punia Pankaj , Olusola Faluyi , Frilling Andrea , Meyer Tim , Kapur Gaurav , Cave Judith , Wadsley Johnathan , Cummins Sebastian , Farrugia David , Starling Naureen , Wall Lucy , Saharan Ruby , Valle Juan

Background: Everolimus, a mammalian target of rapamycin inhibitor, is licensed for use in adult pts with advanced well-differentiated pNETs in the UK. Limited Health-Related Quality-of-Life (HrQOL) data are available for everolimus therapy in these pts.Methods: This prospective study assessed changes in HrQoL (by monthly patient-reported EORTC QLQ-C30, -G.I.NET21 and EQ-5D questionnaires), in pts with pNETs during the first 6 months (mo) of treatment wit...

ea0035p578 | Endocrine tumours and neoplasia | ECE2014

Antiproliferative effects of lanreotide Autogel in patients with enteropancreatic neuroendocrine tumours: results of CLARINET, a large international phase 3 study

Caplin Martyn , Ruszniewski Philippe , Pavel Marianne , Cwikla Jaroslaw , Phan Alexandria , Raderer Markus , Sedlackova Eva , Cadiot Guillaume , Wall Lucy , Rindi Guido , Langley Alison , Blumberg Joelle

Introduction: Data demonstrating antiproliferative effects of somatostatin analogs (SSAs) in enteropancreatic NETs are limited; only one prospective trial so far has shown this for patients with midgut tumors and low hepatic tumor load (HTL). CLARINET is the first large phase 3, randomized, placebo-controlled trial evaluating such effects for the SSA lanreotide in patients with non-functioning enteropancreatic NETs.Methods: Patients who had well/moderate...